Pegfilgrastim-Apgf (Nyvepria): Biosimilar USFDA Approval for the Treatment of Chemotherapy-induced Febrile Neutropenia and Current Updates on Clinical Trials

被引：2
|
作者：
Ali, Faraat [1 ]
Sharma, Kamna [2 ]
Ali, Asad [3 ]
机构：
[1] Botswana Med Regulatory Authority, Lab Serv, Plot 112,Int Finance Pk, Gaborone, Botswana
[2] Indo Soviet Friendship Coll Pharm, Dept Pharmaceut Anal, Moga, Punjab, India
[3] Jamia Hamdard, Sch Chem & Life Sci, Dept Chem, New Delhi, India
来源：
CURRENT DRUG TARGETS | 2022年 / 23卷 / 09期
关键词：
Pegfilgrastim-apgf (Nyvepria); biosimilar; febrile neutropenia; non-myeloid cancer; FDA; anticancer drugs; ONCOLOGY; SAFETY; CT-P6;
D O I：
10.2174/1389450123666220408101152
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Pegfilgrastim-apgf (nyvepria) was currently approved by FDA for the treatment of febrile neutropenia associated with non-myeloid malignancies receiving myelosuppressive anticancer drugs. It was developed by Pfizer, USA. It is a PEGylated leukocyte growth-stimulating factor indicated to reduce the incidence of febrile neutropenia in patients receiving anticancer drugs. Nyvepria is biosimilar to pegfilgrastim, approved by FDA on June 10, 2020. It is the fourth FDA-approved drug for the treatment of infection exhibiting febrile neutropenia. This review abridges the indicators in the development of nyvepria foremost to approval for the treatment of febrile neutropenia (FN), a biosimilar regulatory framework, and current updates on the clinical trials (CTs).
引用
收藏
页码：924 / 932
页数：9
相关论文
共 50 条
  • [41] Colony-stimulating factor (CSF) treatment of patients with chemotherapy-induced febrile neutropenia (FN): A meta-analysis of the randomized clinical trials (RCTs).
    Clark, O
    Djulbegovic, B
    Dale, D
    Crawford, J
    Lyman, GH
    BLOOD, 2002, 100 (11) : 174B - 174B
  • [42] Biosimilar Versus Originator Pegfilgrastim for Preventing Chemotherapy-Induced Neutropenia: A Phase III Randomized, Multicenter, Evaluator-Blinded, Noninferiority Stu
    Kowalyszyn, Ruben D.
    Fein, Luis E.
    Richardet, Martin E.
    Varela, Mirta S.
    Ortiz, Eduardo
    Micheri, Cristian
    Zarba, Juan J.
    Kahl, Susana
    Klimovsky, Ezequiel
    Federico, Andrea A.
    Cassini, Jorge H.
    Cortese, Gustavo
    Lago, Nestor
    JCO GLOBAL ONCOLOGY, 2022, 8 (01)
  • [43] Clinical factors predicting return emergency department visits in chemotherapy-induced febrile neutropenia patients
    Heo, Sejin
    Jeon, Kyeongman
    Park, Boram
    Ko, Ryoung-Eun
    Kim, Taerim
    Hwang, Sung Yeon
    Yoon, Hee
    Shin, Tae Gun
    Cha, Won Chul
    Lee, Se Uk
    AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2023, 67 : 90 - 96
  • [44] Clinical predictive models for chemotherapy-induced febrile neutropenia in breast cancer patients: A validation study
    Chen, Kai
    Zhang, Xiaolan
    Zhu, Liling
    Su, Fengxi
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [45] Clinical Predictive Models for Chemotherapy-Induced Febrile Neutropenia in Breast Cancer Patients: A Validation Study
    Chen, Kai
    Zhang, Xiaolan
    Deng, Heran
    Zhu, Liling
    Su, Fengxi
    Jia, Weijuan
    Deng, Xiaogeng
    PLOS ONE, 2014, 9 (06):
  • [46] A prospective, randomized study of empirical antifungal therapy for the treatment of chemotherapy-induced febrile neutropenia in children
    Caselli, Desiree
    Cesaro, Simone
    Ziino, Ottavio
    Ragusa, Pietro
    Pontillo, Alfredo
    Pegoraro, Anna
    Santoro, Nicola
    Zanazzo, Giulio
    Poggi, Vincenzo
    Giacchino, Mareva
    Livadiotti, Susanna
    Melchionda, Fraia
    Chiodi, Marcello
    Arico, Maurizio
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 158 (02) : 249 - 255
  • [47] Biosimilar epoetin alfa (HX575) for the treatment of chemotherapy-induced anaemia: Development, approval and 10 years' clinical experience
    Aapro, M. S.
    Krendyukov, A.
    Hoebel, N.
    Seidl, A.
    Gascon, P.
    ANNALS OF ONCOLOGY, 2017, 28
  • [48] Cost-minimization analysis for biosimilar pegfilgrastim in the prophylaxis of chemotherapy induced (febrile) neutropenia and expanded access based on budget neutral basis.
    Wang, Weijia
    Balu, Sanjeev
    Campbell, Kim
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [49] Prophylaxis of chemotherapy-induced febrile neutropenia with biosimilar filgrastim: Description of patients, treatment patterns and outcomes in the MONITOR-GCSF study in the breast cancer cohort
    Gascon, Pere
    Aapro, Matti
    Ludwig, Heinz
    Boccadoro, Mario
    Bokemeyer, Carsten
    Turner, Matthew
    Muenzberg, Michael
    Abraham, Ivo
    Denhaerynck, Kris
    MacDonald, Karen
    CANCER RESEARCH, 2015, 75
  • [50] Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations
    Matti Aapro
    Ralph Boccia
    Robert Leonard
    Carlos Camps
    Mario Campone
    Sylvain Choquet
    Marco Danova
    John Glaspy
    Iwona Hus
    Hartmut Link
    Thamer Sliwa
    Hans Tesch
    Vicente Valero
    Supportive Care in Cancer, 2017, 25 : 3295 - 3304
12345